What’s Propelling Alimera Sciences Inc (NASDAQ:ALIM) After Lower Shorts Reported?

June 17, 2018 - By Henry Gaston

Alimera Sciences, Inc. (NASDAQ:ALIM) Logo

Investors sentiment increased to 1.5 in 2018 Q1. Its up 0.50, from 1 in 2017Q4. It increased, as 4 investors sold Alimera Sciences, Inc. shares while 6 reduced holdings. 5 funds opened positions while 10 raised stakes. 28.53 million shares or 0.53% less from 28.68 million shares in 2017Q4 were reported.
Bnp Paribas Arbitrage Sa, a New York-based fund reported 5 shares. Prelude Capital Ltd Liability has invested 0% of its portfolio in Alimera Sciences, Inc. (NASDAQ:ALIM). The New York-based Renaissance Tech Llc has invested 0% in Alimera Sciences, Inc. (NASDAQ:ALIM). Venbio Select Advisor Llc has invested 0.31% in Alimera Sciences, Inc. (NASDAQ:ALIM). Vanguard Group Inc has 2.10 million shares. Citadel Lc has 40,633 shares for 0% of their portfolio. Moreover, Bank & Trust Of Montreal Can has 0% invested in Alimera Sciences, Inc. (NASDAQ:ALIM) for 500 shares. Moreover, Valley Natl Advisers has 0% invested in Alimera Sciences, Inc. (NASDAQ:ALIM). Two Sigma Ltd Liability Co invested 0% of its portfolio in Alimera Sciences, Inc. (NASDAQ:ALIM). Art Limited Liability Company, New York-based fund reported 42,163 shares. Moreover, Barclays Public Ltd Company has 0% invested in Alimera Sciences, Inc. (NASDAQ:ALIM) for 95 shares. Pennsylvania-based Pnc Financial Svcs Group Inc has invested 0% in Alimera Sciences, Inc. (NASDAQ:ALIM). Shufro Rose And Ltd has 0% invested in Alimera Sciences, Inc. (NASDAQ:ALIM) for 10,000 shares. Blackrock holds 0% or 211,921 shares. Armistice Capital Lc has 0.55% invested in Alimera Sciences, Inc. (NASDAQ:ALIM).

Since January 16, 2018, it had 2 insider buys, and 10 sales for $280,303 activity. The insider EISWIRTH RICHARD S JR sold $17,890. 25,500 shares were sold by Ashman Philip, worth $31,475 on Tuesday, January 16. Shares for $31,475 were sold by Holland David on Tuesday, January 16. Green Kenneth sold $14,181 worth of stock. Another trade for 20,000 shares valued at $22,800 was made by ARMISTICE CAPITAL – LLC on Friday, February 2.

The stock of Alimera Sciences Inc (NASDAQ:ALIM) registered a decrease of 2.18% in short interest. ALIM’s total short interest was 757,800 shares in June as published by FINRA. Its down 2.18% from 774,700 shares, reported previously. With 136,900 shares average volume, it will take short sellers 6 days to cover their ALIM’s short positions. The short interest to Alimera Sciences Inc’s float is 2.51%.

The stock increased 2.01% or $0.0169 during the last trading session, reaching $0.8569. About 152,378 shares traded. Alimera Sciences, Inc. (NASDAQ:ALIM) has declined 46.58% since June 17, 2017 and is downtrending. It has underperformed by 59.15% the S&P500.

Alimera Sciences, Inc., a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. The company has market cap of $60.02 million. It focuses on diseases affecting the back of the eye or retina. It currently has negative earnings. The firm offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema , which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness.

Another recent and important Alimera Sciences, Inc. (NASDAQ:ALIM) news was published by Gurufocus.com which published an article titled: “The UK National Institute For Health And Care Excellence To Undertake A Partial Review Of The ILUVIEN …” on June 11, 2018.

Alimera Sciences, Inc. (NASDAQ:ALIM) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.